Quick Links

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity has been approved for AMA PRA Category 1 Credit™.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

New York GU™: 12th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary Malignancies

New York GU™: 12th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary Malignancies

March 15-16, 2019
The Westin New York at Times Square
270 W 43rd St
New York, NY 10036
(212) 201-2700


The congress will focus on key clinical topics in the management of genitourinary (GU) malignancies, including optimal use of chemotherapeutic and local therapies, androgen-deprivation therapies, targeted therapies, radiopharmaceuticals, and immunotherapies. Coverage will include discussions of prognostic/predictive marker application and proactive mitigation of predictable treatment-related adverse effects. Promising new and emerging data in the field will be explored, for example, combining and sequencing treatments across the disease continuum. Key questions concerning the application of landmark clinical trial data (eg, PSA screening, decision making for castrate-sensitive prostate cancer) will be answered during this program.

Now in its 12th year, the 2019 New York GU™ meeting is not to be missed! The meeting will continue its legacy and tradition of providing clinicians with the valuable knowledge and confidence to maintain state-of-the-art care and optimize outcomes for patients with genitourinary malignancies.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with genitourinary (GU) malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other healthcare professionals interested in the treatment of GU malignancies may also participate.

Learning Objectives

After this activity, participants should be better prepared to:

  • Outline the use of patient- and disease-specific characteristics to inform clinical decision-making in the management of patients with GU malignancies
  • Discuss current strategies and practice-changing evidence for the management of patients with GU malignancies across multiple lines of care
  • Explain how to proactively mitigate expected treatment-related toxicities associated with immunotherapeutic and targeted approaches to treat GU cancers
  • Apply emerging clinical trial data for the management of GU malignancies in the context of changing treatment paradigms in the field


Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Program
Yale Cancer Center
New Haven, CT

Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Kimmel Cancer Center
Clinical Director Jefferson Kimmel Cancer Center Network
Thomas Jefferson University
Philadelphia, PA

Become a Member

Forgot Password?
Calendar of Events
Filter By